Raras
Buscar doenças, sintomas, genes...
Doença de Vogt-Koyanagi-Harada
ORPHA:3437CID-10 · H20.8CID-11 · 9A96.1DOENÇA RARA

É uma inflamação crônica e generalizada que afeta os dois olhos (bilateral), em todas as suas camadas (panuveíte), e é caracterizada por granulomas (pequenas aglomerações de células inflamatórias). Normalmente, essa inflamação causa o descolamento da retina (quando ela se solta) devido ao acúmulo de líquido. E, frequentemente, está associada a alterações neurológicas (como a meningite, uma inflamação que atinge o cérebro), problemas de audição e mudanças na pele.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

É uma inflamação crônica e generalizada que afeta os dois olhos (bilateral), em todas as suas camadas (panuveíte), e é caracterizada por granulomas (pequenas aglomerações de células inflamatórias). Normalmente, essa inflamação causa o descolamento da retina (quando ela se solta) devido ao acúmulo de líquido. E, frequentemente, está associada a alterações neurológicas (como a meningite, uma inflamação que atinge o cérebro), problemas de audição e mudanças na pele.

Pesquisas ativas
1 ensaio
15 total registrados no ClinicalTrials.gov
Publicações científicas
1.147 artigos
Último publicado: 2026 Apr
Medicamentos
2 registrados
BEVACIZUMAB, TRIAMCINOLONE ACETONIDE

Tem tratamento?

2 medicamentos registrados
Ver detalhes, fases e interações →
BEVACIZUMABTRIAMCINOLONE ACETONIDE

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Início
All ages
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: H20.8
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

👁️
Olhos
12 sintomas
🧬
Pele e cabelo
4 sintomas
🧠
Neurológico
2 sintomas
👂
Ouvidos
2 sintomas
🫃
Digestivo
1 sintomas
🦴
Ossos e articulações
1 sintomas

+ 16 sintomas em outras categorias

Características mais comuns

90%prev.
Vitiligo
Muito frequente (99-80%)
90%prev.
Cefaleia
Muito frequente (99-80%)
90%prev.
Poliosis
Muito frequente (99-80%)
90%prev.
Comprometimento cognitivo
Muito frequente (99-80%)
90%prev.
Morfologia anormal do cílio
Muito frequente (99-80%)
90%prev.
Cabelo esparso no couro cabeludo
Muito frequente (99-80%)
39sintomas
Muito frequente (10)
Frequente (15)
Ocasional (12)
Sem dados (2)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 39 características clínicas mais associadas, ordenadas por frequência.

Vitiligo
Muito frequente (99-80%)90%
CefaleiaHeadache
Muito frequente (99-80%)90%
Poliosis
Muito frequente (99-80%)90%
Comprometimento cognitivoCognitive impairment
Muito frequente (99-80%)90%
Morfologia anormal do cílioAbnormal eyelash morphology
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico1.147PubMed
Últimos 10 anos200publicações
Pico202566 papers
Linha do tempo
2026Hoje · 2026🧪 2006Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

3 genes identificados com associação a esta condição. Padrão de herança: Multigenic/multifactorial.

FASTumor necrosis factor receptor superfamily member 6Major susceptibility factor inAltamente restrito
FUNÇÃO

Receptor for TNFSF6/FASLG. The adapter molecule FADD recruits caspase CASP8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs CASP8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. FAS-mediated apoptosis may have a role in the induction of peripheral tolerance, in the antigen-stimulated suicide of mature T-cells, or both. The secreted isoforms 2 to 6 block apoptosis (in v

LOCALIZAÇÃO

Cell membraneMembrane raftSecreted

VIAS BIOLÓGICAS (7)
RIPK1-mediated regulated necrosisCASP8 activity is inhibitedRegulation by c-FLIPCaspase activation via Death Receptors in the presence of ligandDimerization of procaspase-8
MECANISMO DE DOENÇA

Autoimmune lymphoproliferative syndrome 1A

A disorder of apoptosis that manifests in early childhood and results in the accumulation of autoreactive lymphocytes. It is characterized by non-malignant lymphadenopathy with hepatosplenomegaly, and autoimmune hemolytic anemia, thrombocytopenia and neutropenia.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
75.4 TPM
Ovário
43.2 TPM
Fibroblastos
41.0 TPM
Pulmão
37.9 TPM
Cervix Endocervix
28.8 TPM
OUTRAS DOENÇAS (4)
autoimmune lymphoproliferative syndrome type 1Vogt-Koyanagi-Harada diseaseBehcet diseaseautoimmune lymphoproliferative syndrome
HGNC:11920UniProt:P25445
PTPN22Tyrosine-protein phosphatase non-receptor type 22Major susceptibility factor inTolerante
FUNÇÃO

Acts as a negative regulator of T-cell receptor (TCR) signaling by direct dephosphorylation of the Src family kinases LCK and FYN, ITAMs of the TCRz/CD3 complex, as well as ZAP70, VAV, VCP and other key signaling molecules (PubMed:16461343, PubMed:18056643). Associates with and probably dephosphorylates CBL. Dephosphorylates LCK at its activating 'Tyr-394' residue (PubMed:21719704). Dephosphorylates ZAP70 at its activating 'Tyr-493' residue (PubMed:16461343). Dephosphorylates the immune system a

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (2)
Phosphorylation of CD3 and TCR zeta chainsTranslocation of ZAP-70 to Immunological synapse
MECANISMO DE DOENÇA

Systemic lupus erythematosus

A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

EXPRESSÃO TECIDUAL(Tecido-específico)
Linfócitos
50.6 TPM
Baço
13.9 TPM
Sangue
12.7 TPM
Intestino delgado
9.6 TPM
Pulmão
8.7 TPM
OUTRAS DOENÇAS (6)
systemic lupus erythematosusVogt-Koyanagi-Harada diseaseoligoarticular juvenile idiopathic arthritisrheumatoid factor-negative juvenile idiopathic arthritis
HGNC:9652UniProt:Q9Y2R2
HLA-DRB1HLA class II histocompatibility antigen, DRB1 beta chainMajor susceptibility factor inRestrito
FUNÇÃO

A beta chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule. In complex with the alpha chain HLA-DRA, displays antigenic peptides on professional antigen presenting cells (APCs) for recognition by alpha-beta T cell receptor (TCR) on HLA-DRB1-restricted CD4-positive T cells. This guides antigen-specific T-helper effector functions, both antibody-mediated immune response and macrophage activation, to ultimately eliminate the infectious agents and transformed cells

LOCALIZAÇÃO

Cell membraneEndoplasmic reticulum membraneLysosome membraneLate endosome membraneAutolysosome membrane

VIAS BIOLÓGICAS (7)
Generation of second messenger moleculesTranslocation of ZAP-70 to Immunological synapsePhosphorylation of CD3 and TCR zeta chainsCo-inhibition by PD-1Downstream TCR signaling
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
1832.6 TPM
Pulmão
1234.8 TPM
Baço
990.6 TPM
Intestino delgado
607.2 TPM
Nervo tibial
598.3 TPM
OUTRAS DOENÇAS (16)
narcolepsy-cataplexy syndromefollicular lymphomaVogt-Koyanagi-Harada diseasepediatric multiple sclerosis
HGNC:4948UniProt:P01911

Medicamentos e terapias

BEVACIZUMABPhase 3

Mecanismo: Vascular endothelial growth factor A inhibitor

TRIAMCINOLONE ACETONIDEPhase 2

Mecanismo: Glucocorticoid receptor agonist

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

530 variantes patogênicas registradas no ClinVar.

🧬 HLA-DRB1: NM_002124.4(HLA-DRB1):c.100+212A>G ()
🧬 HLA-DRB1: NM_002124.4(HLA-DRB1):c.100+1G>A ()
🧬 HLA-DRB1: NM_002124.4(HLA-DRB1):c.100+6T>A ()
🧬 HLA-DRB1: NM_002124.4(HLA-DRB1):c.100+6T>C ()
🧬 HLA-DRB1: NM_002124.4(HLA-DRB1):c.100+15C>T ()
Ver todas no ClinVar

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 33
2Fase 21
·Pré-clínico6
Medicamentos catalogadosEnsaios clínicos· 2 medicamentos · 8 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Doença de Vogt-Koyanagi-Harada

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

1 pesquisa recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

15 ensaios clínicos encontrados, 1 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
698 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 698

#1

Evaluation of Melanin Changes in Acute Vogt-Koyanagi-Harada Disease Using Polarization-Sensitive Optical Coherence Tomography.

Investigative ophthalmology &amp; visual science2026 Jan 05

To examine melanin changes in the RPE and choroid during the acute phase of Vogt-Koyanagi-Harada (VKH) disease using polarization-sensitive optical coherence tomography (PS-OCT). This study included 15 eyes of 8 patients with new-onset VKH disease and 5 eyes of 3 patients with posterior scleritis. PS-OCT captured a 12 × 12 mm area centered on the fovea, and en face images were created for the RPE and choroid. Polarimetric entropy within a 6-mm diameter circle centered on the fovea was calculated and compared between groups. Choroidal polarimetric entropy was significantly lower in eyes with VKH disease than in those with posterior scleritis at baseline (0.296 ± 0.047 vs. 0.392 ± 0.050; P = 0.005; r = 0.64; 95% confidence interval, 0.42-0.74). One month after starting treatment, eyes with VKH disease showed a significant increase in choroidal polarimetric entropy (0.296 ± 0.047 to 0.350 ± 0.075; P = 0.001; r = 0.85; 95% confidence interval, 0.61-0.95), whereas no significant change was observed in eyes with posterior scleritis. RPE polarimetric entropy showed no significant changes between baseline and 1 month, with no differences between groups. PS-OCT revealed that choroidal melanin density decreased during the acute phase of VKH disease and significantly increased after treatment. PS-OCT provides a noninvasive method for observing melanin dynamics in VKH disease and aids in differentiating it from posterior scleritis. PS-OCT could offer valuable insights into the pathology of VKH disease and its potential implications for management.

#2

Natural experiment on neuroinflammatory disease incidence and infection links pre- and post-COVID-19.

Brain : a journal of neurology2026 Mar 05

Infections are recognized triggers for several neuroinflammatory disorders. The coronavirus disease 2019 (COVID-19) pandemic's non-pharmaceutical interventions sharply curtailed pathogen exposure, creating a natural experiment to test infection-disease links. Using Japan's National Claims Database, we first validated the nationwide decline with two strictly infection-dependent conditions-epidemic keratoconjunctivitis and influenza-associated encephalopathy-whose monthly incidences fell by >60% after April 2020. Next, we applied an interrupted time series design, a causal-inference method for longitudinal data, to nine immune-mediated inflammatory diseases. Unsupervised clustering of model-derived level and slope changes identified three data-driven clusters. The first cluster, comprising Guillain-Barré syndrome and acute disseminated encephalomyelitis, showed large, statistically significant level reductions (P < 0.001), particularly in women, consistent with infection-susceptible pathophysiology. The second cluster, including myasthenia gravis and optic neuritis, exhibited transient declines followed by significant positive post-intervention slopes (P < 0.001), suggesting deferred diagnosis, treatment interruption or immune rebound. The third cluster, consisting of sarcoidosis, neuromyelitis optica, multiple sclerosis, Vogt-Koyanagi-Harada disease and Behçet's disease, remained stable, suggesting limited or complex infectious links. These data-driven trajectories mirror clinical pathophysiology and demonstrate that reduced pathogen exposure affects neuroinflammatory disease onset to varying degrees. This framework supports infection-related risk stratification, preventive strategies and continuity planning in neuroimmunology practice.

#3

Seasonal Variations of Vogt-Koyanagi-Harada Disease in Japan: A Study on Long-Term Trends and the Influence of Coronavirus Disease 2019 (COVID-19).

Ophthalmology science2026 Jan

To investigate seasonal trends in the onset of Vogt-Koyanagi-Harada (VKH) disease in Japan and evaluate the influence of the coronavirus disease 2019 (COVID-19) pandemic, including severe cases and vaccination campaigns, on disease onset. A retrospective cohort study using clinical records and public health data. A total of 320 Japanese VKH patients with a known month of onset who were initially treated at Yokohama City University Hospital between April 2007 and March 2024. The monthly distribution of VKH onset cases was assessed using the Roger test to determine seasonality before and after the COVID-19 pandemic. Severe COVID-19 case data (April 2020 to March 2024) were obtained from government sources. The COVID-19 vaccine administration data (April 2021 to March 2024) were collected from a major local clinic. Multiple linear regression was used to evaluate the temporal relationship between VKH onset and severe COVID-19 cases or vaccination, incorporating current-month (lag0), 1-month lag (lag1), and 2-month lag (lag2) predictors. Monthly number of VKH onset cases, seasonal trends, and statistical associations with COVID-19-related variables. Seasonal variation was significant in VKH onset both before (P = 0.02) and after (P < 0.001) the pandemic, with a shift in peak onset from spring to late summer/fall. Vogt-Koyanagi-Harada onset was significantly associated with severe COVID-19 cases in the current month (β = 0.097; P = 0.02) and with COVID-19 vaccination counts with a 1-month delay (β = 0.83; P = 0.002). The regression models showed moderate to strong explanatory power (adjusted R 2 = 0.52 and 0.80, respectively). This study revealed a postpandemic shift in the seasonal distribution of VKH onset in Japan, with peaks aligning with increased severe COVID-19 infections in the current month and vaccination activity in the preceding month. The findings suggest that both acute viral immune responses and delayed vaccine-induced immunity may contribute to VKH onset, highlighting the need for further investigation into the immunological mechanisms linking COVID-19 and autoimmune disease expression. The authors have no proprietary or commercial interest in any materials discussed in this article.

#4

Choroidal Osteoma with Focal Choroidal Excavation Masquerading as Active Vogt-Koyanagi-Harada: A Case Report.

Case reports in ophthalmology2026

Choroidal osteoma is a rare, benign ossifying tumor of the choroid that can present with clinical features overlapping those of inflammatory choroidal lesions. In patients with a history of Vogt-Koyanagi-Harada (VKH) disease, distinguishing between inflammatory relapse and non-inflammatory choroidal pathology can be particularly challenging. This case report highlights the diagnostic pitfalls associated with choroidal osteoma in the setting of prior VKH and underscores the importance of comprehensive multimodal imaging to ensure accurate diagnosis and appropriate management. A 39-year-old female with a 14-year history of VKH disease, who had been stable off immunosuppressive therapy since 2016, presented in early 2024 with a 7-week history of cloudy vision in the right eye. She was initially diagnosed with a recurrent posterior VKH relapse and treated with high-dose intravenous corticosteroids followed by an oral taper, resulting in symptomatic improvement. However, further multimodal imaging - including wide-field fundus photography, optical coherence tomography (OCT), fundus autofluorescence, OCT angiography, fluorescein angiography, enhanced depth imaging OCT (EDI-OCT), and B-scan ultrasonography - revealed a yellow-orange, minimally elevated subretinal lesion associated with focal choroidal excavation. These findings were consistent with choroidal osteoma and confirmed by EDI-OCT and B-scan ultrasonography. This case illustrates a rare instance of choroidal osteoma masquerading as a posterior relapse of VKH disease. It emphasizes the critical importance of differentiating inflammatory from non-inflammatory choroidal lesions in patients with a history of uveitis. Careful interpretation of multimodal imaging is essential to avoid misdiagnosis, prevent unnecessary immunosuppressive treatment, and reduce associated risks, ultimately leading to improved patient outcomes.

#5

Incidence of Cataract Surgery and Postoperative Visual Acuity Outcomes in Patients with Vogt-Koyanagi-Harada Disease.

Ocular immunology and inflammation2026 Mar 03

To determine the incidence and predictive factors of visually significant cataracts requiring cataract surgery in patients with Vogt-Koyanagi-Harada (VKH) disease and to evaluate postoperative visual acuity (VA) outcomes. Medical records of 100 patients (197 phakic eyes) diagnosed with VKH between 2010 and 2023 were reviewed. Kaplan-Meier analysis was used to estimate the cumulative incidence of cataract surgery. Longitudinal postoperative VA outcomes were analyzed using a linear mixed-effects model. Forty-one eyes from 24 patients developed visually significant cataracts requiring surgery (incidence rate, 5.4% per eye-year; 95% CI, 4.0-7.3). The cumulative incidence of cataract surgery was 27.9% at 5 years after disease onset. Age > 45 years at VKH presentation (adjusted hazard ratio [aHR] = 6.7, p = 0.001), male sex (aHR = 3.8, p = 0.007), prior glaucoma medication use (aHR = 6.3, p = 0.015), prior regional corticosteroid injection (aHR = 8.3, p = 0.015), and inactive uveitis at presentation (aHR = 22.0, p < 0.001) were associated with an increased incidence of cataract surgery. The modeled mean VA improved from 1.2 logarithm of the minimum angle of resolution (logMAR) preoperatively to 0.3 logMAR at 6 months postoperatively. Systemic immunomodulatory treatment (IMT) use (adjusted odds ratio [aOR] = 14.2, p = 0.034) and absence of prior regional corticosteroid injection (aOR = 19.3, p = 0.009) increased the likelihood of achieving a VA of ≥20/40 at 6 months postoperatively. Patients with VKH have a moderate risk of cataract surgery. Cataract surgery is associated with substantial and sustained VA improvement. More favorable outcomes were observed in eyes receiving IMT and in those without a history of regional corticosteroid injection.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC881 artigos no totalmostrando 195

2026

Choroidal Osteoma with Focal Choroidal Excavation Masquerading as Active Vogt-Koyanagi-Harada: A Case Report.

Case reports in ophthalmology
2026

Incidence of Cataract Surgery and Postoperative Visual Acuity Outcomes in Patients with Vogt-Koyanagi-Harada Disease.

Ocular immunology and inflammation
2026

VKH-Like Syndrome in a Patient on Tofacitinib.

Journal of vitreoretinal diseases
2026

Vogt-Koyanagi-Harada Disease in Paediatric Population: Case Series and Literature Review.

Ocular immunology and inflammation
2026

Vogt-Koyanagi-Harada disease under the lens: Insights from multimodal ocular imaging.

Progress in retinal and eye research
2026

Co-occurrence of Vogt-Koyanagi-Harada disease, diabetic retinopathy, and advanced chronic kidney disease: a case report.

Frontiers in medicine
2026

Changing paediatric uveitis patterns in Italy: an eight-year experience from the Reggio Emilia Uveitis clinic.

International ophthalmology
2026

Treatment Initiation within the Therapeutic Window of Opportunity in Acute Uveitic Phase of Vogt-Koyanagi-Harada Disease Preserves Photoreceptor Function.

Ocular immunology and inflammation
2026

Methodological Limitations in Prognostic Modelling for Refractory Vogt-Koyanagi-Harada Disease: Response.

Clinical &amp; experimental ophthalmology
2026

Full-field electroretinogram (ffERG) over 48 months correlates with baseline retinal dysfunction in Vogt-Koyanagi-Harada disease: a longitudinal study.

Documenta ophthalmologica. Advances in ophthalmology
2026

Retinal structure and function recovery over five years in Vogt-Koyanagi-Harada disease using adaptive optics and microperimetry.

Scientific reports
2026

Evaluation of Melanin Changes in Acute Vogt-Koyanagi-Harada Disease Using Polarization-Sensitive Optical Coherence Tomography.

Investigative ophthalmology &amp; visual science
2026

Quantitative Ultra-Widefield Imaging Measurement of Fundus Depigmentation in Vogt-Koyanagi-Harada Disease.

Ocular immunology and inflammation
2026

Demography, clinical features, and outcomes of Vogt-Koyanagi-Harada disease presenting with bullous exudative retinal detachment.

Indian journal of ophthalmology
2026

Optical coherence tomography angiography features of inflammatory choroidal neovascularizaton in Vogt-Koyanagi-Harada disease.

Indian journal of ophthalmology
2026

Segmental choroidal vascularity in Acute Vogt-Koyanagi-Harada disease.

International journal of retina and vitreous
2026

Methodological Limitations in Prognostic Modelling for Refractory Vogt-Koyanagi-Harada Disease.

Clinical &amp; experimental ophthalmology
2025

Efficacy of Tumor Necrosis Factor-α Inhibitor Adalimumab in Chronic Recurrent Vogt-Koyanagi-Harada Disease.

Pharmaceuticals (Basel, Switzerland)
2026

Near-Infrared Autofluorescence in Non-Infectious Uveitis: A Review.

Ocular immunology and inflammation
2025

Two cases of juxtapapillary retinal astrocytic hamartoma: a multimodal imaging study.

BMC ophthalmology
2026

Natural experiment on neuroinflammatory disease incidence and infection links pre- and post-COVID-19.

Brain : a journal of neurology
2025

Factors associated with the avoidance of glaucoma surgery in secondary glaucoma due to ocular inflammatory disease.

Journal of ophthalmic inflammation and infection
2025

Vogt-Koyanagi-Harada disease-like immune-related adverse event with concurrent exacerbation of uveitis and vitiligo.

European journal of dermatology : EJD
2025

Hyperreflective Choroidal Foci: A Comprehensive Review.

Journal of ophthalmic &amp; vision research
2025

Analysis of the Retinal Microcirculation in Chinese Patients With Vogt-Koyanagi-Harada Disease by Optical Coherence Tomography Angiography.

Translational vision science &amp; technology
2026

Epidemiological Characterization of Uveitis in Pediatric Population: A Systematic Review and Meta Analysis.

Ocular immunology and inflammation
2025

Weekly adalimumab: A promising approach for managing refractory non-infectious chronic pediatric uveitis.

Journal francais d'ophtalmologie
2026

Single-cell RNA sequencing reveals beneficial mechanisms of Exendin-4 in autoimmune uveitis.

Biochemical pharmacology
2026

DIAGNOSTIC PERFORMANCE OF MACHINE LEARNING TECHNOLOGY USING OPTICAL COHERENCE TOMOGRAPHIC IMAGE IN RETINAL DISEASES PRESENTED WITH SUBRETINAL FLUID.

Retina (Philadelphia, Pa.)
2025

Secondary Adrenal Insufficiency and Iatrogenic Cushing's Syndrome in a 13-Year-Old Male With Vogt-Koyanagi-Harada Disease: A Case Report.

Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates &amp; Practitioners
2025

Early imaging and systemic findings in pediatric Vogt-Koyanagi-Harada disease.

Journal francais d'ophtalmologie
2025

Secondary Choroidal Osteoma in the Setting of Uveal Pathology: 4 Case Reports and Review.

Ocular oncology and pathology
2026

Seasonal Variations of Vogt-Koyanagi-Harada Disease in Japan: A Study on Long-Term Trends and the Influence of Coronavirus Disease 2019 (COVID-19).

Ophthalmology science
2025

Diagnostic and Management Challenges in Atypical Central Serous Chorioretinopathy Mimicking Vogt-Koyanagi-Harada Disease: A Case Report.

Cureus
2025

Clinical characteristics and long-term outcomes of Vogt-Koyanagi-Harada disease in pediatric age group.

BMC ophthalmology
2025

Influenza-Associated Ocular Complications: A Comprehensive Review of Viral Subtypes, Clinical Presentations, and Vaccination Risks.

Vaccines
2025

Safety and efficacy of rituximab in refractory noninfectious uveitis and scleritis.

Journal of ophthalmic inflammation and infection
2025

An Eye for an Eye, An Ear for an Ear: A Midwestern Case Report of Vogt-Koyanagi-Harada Disease.

WMJ : official publication of the State Medical Society of Wisconsin
2025

Dynamics of color vision recovery in Vogt-Koyanagi-Harada disease: a longitudinal study using cone contrast test and adaptive optics imaging.

Journal of ophthalmic inflammation and infection
2025

Ultrawidefield Optical Coherence Tomography Angiography in the Mid-Periphery and Macula of Vogt-Koyanagi-Harada Disease.

Ocular immunology and inflammation
2025

Clinical characteristics and visual outcome of Vogt Koyanagi Harada disease patients in a specialized eye hospital in Nepal.

Journal of Nepal Health Research Council
2025

In the Race Against Time to Treat Vogt-Koyanagi-Harada Disease.

Clinical &amp; experimental ophthalmology
2025

Epidemiology and Clinical Features of Uveitis in Southwestern Japan: Laterality and Long-Term Visual Prognosis Based on the Anatomical and Epidemiological Classification.

Ocular immunology and inflammation
2025

Clinical features, treatment and outcomes of dabrafenib-associated uveitis.

Investigational new drugs
2025

Use of Imaging Modalities in Vogt-Koyanagi-Harada Disease: An Overview.

Ceska a slovenska oftalmologie : casopis Ceske oftalmologicke spolecnosti a Slovenske oftalmologicke spolecnosti
2024

Vogt-Koyanagi-Harada Disease in which Poliosis and Alopecia Occurred after a Long Period of Time.

Acta dermatovenerologica Croatica : ADC
2025

Predictive factors at initial visit for sunset glow fundus in Vogt-Koyanagi-Harada disease.

Scientific reports
2025

Acute interstitial nephritis and probable Vogt-Koyanagi-Harada disease following COVID-19 infection: a case report.

Journal of medical case reports
2025

Prevalence and clinical characteristics of ocular sarcoidosis among non-infectious uveitis in a Chinese tertiary ophthalmic center: a retrospective observational study.

BMC ophthalmology
2025

Retrospective analysis of Vogt-Koyanagi-Harada's recurrence within a case series of nineteen patients followed between 2003 and 2018 in an academic center.

Journal of ophthalmic inflammation and infection
2025

Revising the role of cerebrospinal fluid pleocytosis as a diagnostic criterion in Vogt-Koyanagi-Harada disease.

Eye (London, England)
2025

Alterations of the Enteric Virome in Vogt-Koyanagi-Harada Disease.

Investigative ophthalmology &amp; visual science
2025

Tonic Pupils in a Young Female with Vogt Koyanagi Harada Disease.

Klinische Monatsblatter fur Augenheilkunde
2025

Vogt Koyanagi Harada disease with bilateral disc edema diagnosed as Arnold Chiari malformation with papilledema: The blurred margin between ophthalmology and neurology.

Indian journal of ophthalmology
2025

Comparative study of efficacy and safety of pulse versus half-pulse steroid therapy for Vogt-Koyanagi-Harada Disease.

Japanese journal of ophthalmology
2025

Optical Coherence Tomography Biomarkers in Acute Vogt-Koyanagi-Harada Disease: Clinical Significance of Hyperreflective Outer Nuclear Layer and Bacillary Layer Detachment.

Ocular immunology and inflammation
2025

Non-infectious uveitis: a multicenter study from Argentina.

International ophthalmology
2025

Long-Term Outcomes of Pediatric Vogt-Koyanagi-Harada Disease.

Ocular immunology and inflammation
2025

Clinical Characteristics, Recurrences, and Complications in the Mexican Pediatric Patients with Vogt-Koyanagi-Harada Disease.

Ocular immunology and inflammation
2025

Bacillary layer detachment in acute Vogt-Koyanagi-Harada disease: an early predictor of long-term complications in a Brazilian cohort.

International journal of retina and vitreous
2025

Safety of Mycophenolate Mofetil in the Treatment of Non-Infectious Uveitis and Sclerouveitis in Japanese Patients: A Feasibility Study.

Ocular immunology and inflammation
2025

Predictive Factors for Uveitis Refractory to Treatment in Initial-Onset Acute Vogt-Koyanagi-Harada Disease.

Clinical &amp; experimental ophthalmology
2025

Oleic acid regulates CD4+ T cells differentiation by targeting ODC1-mediated STAT5A phosphorylation in Vogt-Koyanagi-Harada disease.

Phytomedicine : international journal of phytotherapy and phytopharmacology
2025

Efficacy of azathioprine as a first-line therapy in new onset of acute Vogt-Koyanagi-Harada disease in the Indian population.

Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society
2025

Optical Density Analysis of Subretinal Fluid in Vogt Koyanagi Harada Disease, Posterior Scleritis and Acute Central Serous Chorioretinopathy.

Ocular immunology and inflammation
2025

Occult invasive fungal sinusitis in a patient with acute Vogt-Koyanagi-Harada Disease (VKHD).

Retinal cases &amp; brief reports
2025

Vogt-Koyanagi-Harada disease in a patient with retinitis pigmentosa in one eye and pigmented paravenous retinochoroidal atrophy in the other eye.

American journal of ophthalmology case reports
2025

The epidemiology of uveitis: comparison of its causes and visual outcomes between three-tiered medical facilities in Ube city.

Scientific reports
2025

Unilateral choroidal detachment in an elderly patient with Vogt-Koyanagi-Harada disease: a case report and literature review.

Frontiers in immunology
2025

Inadequacies in uveitis: misnomers, incongruencies, persistence of obsolete terminologies & inappropriate guidelines, treatment inadequacies, and misinterpretations.

Journal of ophthalmic inflammation and infection
2025

Cutaneous Granulomatous Inflammation in Vogt-Koyanagi-Harada Disease.

Ophthalmology
2025

Effect of prednisone plus either adalimumab or cyclosporine on dermatological symptoms in Vogt-Koyanagi-Harada disease: Systemic outcomes from a randomized trial.

Journal of the American Academy of Dermatology
2025

A Case of Vogt-Koyanagi-Harada Disease: Diagnosis Based on the Presence of Vitiligo and Sunset Glow Fundus Without Ocular Symptoms.

Cureus
2025

Bilateral Serous Retinal Detachment as an Initial Manifestation of Systemic Lupus Erythematosus due to Hypoalbuminemia: A Case Report.

Case reports in ophthalmology
2025

Outcomes of Corticosteroids Combined with 15 Mg/Week Methotrexate as Initial Treatment for Acute Vogt-Koyanagi-Harada Disease.

Ocular immunology and inflammation
2025

Serous retinal detachment secondary to bilateral choroidal osteoma successfully treated with subscleral sclerectomy: A case report.

American journal of ophthalmology case reports
2025

Demographic Features, Diagnoses and Real-World Clinical Management of Uveitis in Japan.

Ocular immunology and inflammation
2025

Vogt-Koyanagi-Harada disease-like uveitis induced by nivolumab in metastatic renal cell carcinoma.

IJU case reports
2024

Atypical presentation of acute retinal necrosis mimicking Vogt-Koyanagi-Harada disease leading to misdiagnosis: a case report.

Frontiers in medicine
2024

Automatic measurement of choroidal thickness with swept-source optical coherence tomography in chronic Vogt-Koyanagi-Harada disease: 3 years' follow-up.

Journal of ophthalmic inflammation and infection
2025

Retromode Infrared Scanning Laser Ophthalmoscopy in Vogt-Koyanagi-Harada Disease.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
2025

Early Changes in Ocular Biomarkers in Patients with Vogt-Koyanagi-Harada Disease after Pulse Steroid Therapy.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde
2024

Cabozantinib-Associated Exudative Retinal Detachment and Choroiditis: A Case Report.

Journal of current ophthalmology
2024

Evaluation of the Activity of Vogt-Koyanagi-Harada Disease; A Comparison of Indocyanine Green Angiography Scoring, Enhanced Depth Imaging Optical Coherence Tomography, and Choroidal Vascularity Index.

Journal of current ophthalmology
2025

Reduced contrast sensitivity function and outer retina thickness in convalescent Vogt-Koyanagi-Harada disease.

Eye (London, England)
2025

Vogt-Koyanagi-Harada Disease Presenting as Papillitis vs. Classic Serous Retinal Detachment: A Comparative Analysis of Outcomes.

Ocular immunology and inflammation
2024

Managing Vogt-Koyanagi-Harada disease during pregnancy with steroid pulse therapy: A case report.

World journal of clinical cases
2024

A case of unilateral focal choroidal excavation in Vogt-Koyanagi-Harada disease; case report.

Heliyon
2024

Vogt-Koyanagi-Harada-Like Uveitis Secondary to Pembrolizumab in Metastatic Gastric Cancer: A Case Report and Review of the Literature.

Case reports in oncology
2025

Effects of pregnancy on the clinical course and treatment outcomes of Vogt-Koyanagi-Harada disease.

Indian journal of ophthalmology
2025

Association between axial length and uveitis.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
2024

Clinical features and multimodal imaging of primary choroidal lymphoma.

Japanese journal of ophthalmology
2024

Transcription factor EGR2 alleviates autoimmune uveitis via activation of GDF15 to modulate the retinal microglial phenotype.

Proceedings of the National Academy of Sciences of the United States of America
2024

Unilateral Vogt-Koyanagi-Harada Disease With Two Distinct Choroidal Neovascular Membranes: A Case Report.

Cureus
2025

Association Between Baseline Macular Morphologic Features on Optical Coherence Tomography and Visual Outcomes in Patients with Vogt-Koyanagi-Harada Disease.

Ocular immunology and inflammation
2025

VASCULAR CHANGES AND IRREVERSIBLE COMPLICATIONS IN 120° FUNDUS USING WIDEFIELD SWEPT-SOURCE OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IN VOGT-KOYANAGI-HARADA DISEASE.

Retina (Philadelphia, Pa.)
2024

Vogt-Koyanagi-Harada Syndrome: A Case Report.

Cureus
2024

Clinical characteristics, treatment, and outcomes of pembrolizumab-induced uveitis.

Investigational new drugs
2024

A Case of Vogt-Koyanagi-Harada Disease and Retinal Peri-Phlebitis in a Patient With Presumed Ocular Tuberculosis.

Cureus
2024

CHANGES IN SCLERAL THICKNESS IN THE ACUTE PHASE OF VOGT-KOYANAGI-HARADA DISEASE.

Retina (Philadelphia, Pa.)
2024

Atypical Central Serous Chorioretinopathy Masquerading as Vogt-Koyanagi-Harada Disease: A Case Report.

Case reports in ophthalmology
2024

Application of Ophthalmic Electrophysiology in Inflammatory Disorders of Retina and Optic Nerve.

Journal of clinical medicine
2024

Efficacy of adalimumab in noninfectious pediatric uveitis: Analysis of 29 eyes from a tertiary eye care center in India.

Indian journal of ophthalmology
2024

Choroidal venous overload in Vogt‒Koyanagi‒Harada disease.

Eye (London, England)
2024

Bilateral peripapillary choroidal neovascular membranes in Vogt-Koyanagi-Harada disease.

BMJ case reports
2025

Dynamic Changes of Fundus and Predictors of Visual Prognosis in New-Onset Vogt-Koyanagi-Harada Disease.

Ocular immunology and inflammation
2024

Outcomes in Patients With Vogt-Koyanagi-Harada Disease From the First-Line Antimetabolites for Steroid-Sparing Treatment Uveitis Trial.

American journal of ophthalmology
2024

Effect of the COVID-19 pandemic on Vogt-Koyanagi-Harada disease.

Scientific reports
2024

Development of Vogt-Koyanagi-Harada disease-like uveitis during treatment by anti-programmed death-1 antibody: a case report.

BMC ophthalmology
2024

Predictive factors and adalimumab efficacy in managing chronic recurrence Vogt-Koyanagi-Harada disease.

BMC ophthalmology
2024

Vogt-Koyanagi-Harada Disease: A Narrative Review.

Cureus
2024

Cost-Effectiveness Analysis of Adalimumab Versus Cyclosporine for Vogt-Koyanagi-Harada Disease: A Randomized Controlled Study.

Current eye research
2024

Enhanced depth imaging optical coherence tomography features of two types of Vogt-Koyanagi-Harada disease: fuzzy or lost pattern of the choroidal vasculature is of diagnostic value.

Frontiers in medicine
2025

Paediatric non-infectious granulomatous uveitis: a retrospective cohort study.

Rheumatology (Oxford, England)
2025

Clinical and Transcriptional Profiles Reveal the Treatment Effect of Adalimumab in Patients with Initial-Onset and Recurrent Vogt-Koyanagi-Harada Disease.

Ocular immunology and inflammation
2024

Unveiling Key Pathological Indicators for Disease Progression in Vogt Koyanagi Harada Disease and Sympathetic Ophthalmia Through Advanced Choroidal Volume Analysis.

Ocular immunology and inflammation
2024

New-onset or relapse of uveitis after rapid spreading of COVID-19 infection in China and risk factor analysis for relapse.

BMC ophthalmology
2024

Vogt-Koyanagi-Harada disease after SARS-CoV-2 infection: Case report and literature review.

Immunity, inflammation and disease
2024

Vogt-Koyanagi-Harada Disease.

Ocular immunology and inflammation
2023

Vitiligo as a First Sign of Vogt-Koyanagi-Harada Disease.

Acta dermatovenerologica Croatica : ADC
2024

Blood Whispers: Exploring Hematologic Indicators for Diagnosing and Predicting Severity of Vogt-Koyanagi-Harada Syndrome.

Ocular immunology and inflammation
2024

A case report: co-occurrence of probable Vogt-Koyanagi-Harada disease and diabetic retinopathy.

BMC ophthalmology
2024

Intravascular large B-cell lymphoma of the eye: Literature review and new findings.

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)
2024

Vogt-Koyanagi-Harada disease developed during chemotherapy for Hodgkin lymphoma: a case report.

BMC ophthalmology
2024

Vogt-Koyanagi-Harada disease in pregnancy: Case report and review of 32 patients in the literature.

Clinical case reports
2024

Pretreatment ocular blood flow and retinal oxygen metabolism in the acute uveitic phase is associated with final outcome in Vogt-Koyanagi-Harada disease.

Acta ophthalmologica
2024

An Analysis of the clinical and investigative profile of uveitis in the elderly: First case series from India.

Indian journal of ophthalmology
2023

Single Low-dose Suprachoroidal Triamcinolone Acetonide Injection in Macular Edema Secondary to Noninfectious Posterior Uveitis.

Middle East African journal of ophthalmology
2025

Sympathetic ophthalmia or Vogt-Koyanagi-Harada disease: Don't judge a book by its cover.

Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society
2024

Vogt-Koyanagi-Harada Disease: The Clinical Spectrum and Management of Case Series in a Tertiary Eye Centre in Northern Part Of Malaysia.

Ceska a slovenska oftalmologie : casopis Ceske oftalmologicke spolecnosti a Slovenske oftalmologicke spolecnosti
2024

Ultrasonographic study of the orbit as an early diagnostic tool in Vogt Koyanagi Harada disease (VKH): A case report.

Heliyon
2024

A Novel Risk Stratification-Based Immunomodulatory Treatment Strategy for Vogt-Koyanagi-Harada Disease.

American journal of ophthalmology
2024

Association between advanced glycation end products and uveitis/scleritis activity in patients with active immune-mediated ocular inflammatory diseases.

International ophthalmology
2024

Proteomic profiling of aqueous humor-derived exosomes in Vogt-Koyanagi-Harada disease and Behcet's uveitis.

Clinical immunology (Orlando, Fla.)
2024

Reactivation of previously controlled Vogt-Koyanagi-Harada disease more than 46 years following COVID-19 vaccination: a case study.

The Journal of international medical research
2024

OR11H1 Missense Variant Confers the Susceptibility to Vogt-Koyanagi-Harada Disease by Mediating Gadd45g Expression.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)
2023

Classification of Peripheral Blood Leukocyte Phenotypes and Serum Cytokines in Vogt-Koyanagi-Harada Disease before and after Glucocorticoid Therapy.

Journal of clinical medicine
2024

Prognostic value of pretreatment indocyanine green angiography in the acute uveitic phase of Vogt-Koyanagi-Harada disease.

Acta ophthalmologica
2024

Comparisons of choroidal blood flow velocity between initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease and acute central serous chorioretinopathy.

Eye (London, England)
2024

Vogt-Koyanagi-Harada disease-like uveitis after drug therapy including BRAF/MEK inhibitors in melanoma patients with HLA-DRB1*04.

The Journal of dermatology
2024

Etiological Diagnosis of Uveitis: Contribution of the of the Extra-Ophthalmological Clinical Examination.

Ocular immunology and inflammation
2024

SS OCT and OCT-A Findings in Convalescent Inactive Vogt-Koyanagi-Harada Disease.

Ocular immunology and inflammation
2024

The Causes of Optic Disc Edema in Patients Presenting With Significantly Compromised Vision.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
2023

Epidemiology of Pediatric Uveitis.

Ocular immunology and inflammation
2023

Clinical Features of Pediatric Uveitis at a Tertiary Referral Center in the Western Region of Japan.

Ocular immunology and inflammation
2023

Berlin's Edema with Atypical Optical Coherence Tomography Findings: A Case Report.

Case reports in ophthalmology
2024

The skin, the eyes, and the ears in Vogt-Koyanagi-Harada disease (VKHD).

Clinical rheumatology
2023

Vogt-Koyanagi-Harada Disease and COVID.

Journal of clinical medicine
2023

A de novo missense mutation in MPP2 confers an increased risk of Vogt-Koyanagi-Harada disease as shown by trio-based whole-exome sequencing.

Cellular &amp; molecular immunology
2023

Identification of FCER1G as a cyclosporin A plus corticosteroid sensitization gene in female patients with Vogt-Koyanagi-Harada disease.

Clinical immunology (Orlando, Fla.)
2023

Polyautoimmunity manifest as inflammatory myopathy, uveitis, and progressive cutaneous depigmentation in a mixed breed dog: a case report.

BMC veterinary research
2023

Uveitis associated with immune checkpoint inhibitors or BRAF/MEK inhibitors in patients with malignant melanoma.

Melanoma research
2023

Vogt-Koyanagi-Harada disease in a patient with extreme anisometropia.

American journal of ophthalmology case reports
2023

Autoimmune uveitis in Behçet's disease and Vogt-Koyanagi-Harada disease differ in tissue immune infiltration and T cell clonality.

Clinical &amp; translational immunology
2023

Vogt-Koyanagi-Harada disease with a unilateral presentation in a patient with marijuana overuse: Role of multimodal imaging in suspected patients.

Clinical case reports
2023

VOGT-KOYANAGI-HARADA DISEASE-LIKE UVEITIS IN A PATIENT WITH ADVANCED MELANOMA TREATED BY SEQUENTIAL ADMINISTRATION OF NIVOLUMAB AND DABRAFENIB/TRAMETINIB THERAPY.

Retinal cases &amp; brief reports
2023

HLA-DRB1*04:05 is involved in the development of Vogt-Koyanagi-Harada disease-like immune-related adverse events in patients receiving immune checkpoint inhibitors.

Scientific reports
2023

Dexamethasone intravitreal implant for macular edema and some other rare indications in uveitis.

Medicine international
2023

Bibliometric analysis of the Vogt‒Koyanagi‒Harada disease literature.

International ophthalmology
2023

Dural and Leptomeningeal Diseases: Anatomy, Causes, and Neuroimaging Findings.

Radiographics : a review publication of the Radiological Society of North America, Inc
2023

Bilateral exudative retinal detachments after subretinal gene therapy with voretigene neparvovec-rzyl for RPE65 Leber Congenital Amaurosis.

American journal of ophthalmology case reports
2023

Association of Retinal Pigment Epithelium Reflectivity on Optical Coherence Tomography with Recurrence of Vogt-Koyanagi-Harada Disease: A Retrospective Observational Study.

Clinical ophthalmology (Auckland, N.Z.)
2023

Incidence and Risk Factors of Recurrent Anterior Uveitis in Initial Acute-Onset Vogt-Koyanagi-Harada Disease.

Korean journal of ophthalmology : KJO
2023

Epigenome-wide association study identifies Vogt-Koyanagi-Harada disease-associated DNA methylation loci in Chinese.

Experimental eye research
2023

Alterations in the optic nerve and retina in patients with COVID-19. A theoretical review.

Archivos de la Sociedad Espanola de Oftalmologia
2023

A randomized non-inferiority trial of therapeutic strategy with immunosuppressants versus biologics for Vogt-Koyanagi-Harada disease.

Nature communications
2023

A COVID-19 perspective of Vogt-Koyanagi-Harada disease.

Indian journal of ophthalmology
2023

Surgical management for treatment-resistant cases of inflammatory exudative retinal detachment: Mission impossible?

Indian journal of ophthalmology
2023

CLINICAL FEATURES AND PROGNOSTIC VALUE OF BACILLARY LAYER DETACHMENT IN ACUTE VOGT-KOYANAGI-HARADA DISEASE.

Retina (Philadelphia, Pa.)
2023

Clinical features, diagnosis, and management of COVID-19 vaccine-associated Vogt-Koyanagi-Harada disease.

Human vaccines &amp; immunotherapeutics
2023

Does Subretinal Fluid Optical Density Ratio Differ Among the Eyes with Acute Central Serous Chorioretinopathy,Vogt Koyanagi Harada Disease and Choroidal Hemangioma: A Cross-sectional Study.

Photodiagnosis and photodynamic therapy
2023

Identification of Hif1α as a Potential Participant in Autoimmune Uveitis Pathogenesis Using Single-Cell Transcriptome Analysis.

Investigative ophthalmology &amp; visual science
2023

HIGH LONG-TERM DRUG-FREE REMISSION RATE FOR ACUTE VOGT-KOYANAGI-HARADA DISEASE WITH AN APPROPRIATE IMMUNOSUPPRESSIVE REGIMEN.

Retina (Philadelphia, Pa.)
2023

Association of ZC3HAV1 single nucleotide polymorphisms with the susceptibility of Vogt-Koyanagi-Harada Disease.

BMC medical genomics
2023

Gut microbial signatures and their functions in Behcet's uveitis and Vogt-Koyanagi-Harada disease.

Journal of autoimmunity
2023

Immunosuppressive therapy for Vogt-Koyanagi-Harada disease: a retrospective study and review of literature.

Journal of ophthalmic inflammation and infection
2023

Classification of Vogt-Koyanagi-Harada disease using feature selection and classification based on wide-field swept-source optical coherence tomography angiography.

Frontiers in bioengineering and biotechnology
2023

Very early OCT response to intravenous pulse steroid in Vogt-Koyanagi-Harada disease.

BMJ case reports
2023

Management of Atypical Central Serous Chorioretinopathy Mimicking Vogt-Koyanagi-Harada Disease.

Journal of vitreoretinal diseases
2023

Acute phase clinical manifestations of patients with Vogt-Koyanagi-Harada disease in Southern China.

BMC ophthalmology
2023

COVID Vaccine-Associated Uveitis.

Ocular immunology and inflammation
2023

Changes of Peripapillary Capillary Density in Patients with Vogt-Koyanagi-Harada Disease Evaluated by Optical Coherence Tomography Angiography.

Journal of ophthalmology
2023

COVID-19 Developed During Systemic Steroid Therapy for Vogt-Koyanagi-Harada Disease: A Case Report.

Ocular immunology and inflammation
2023

Vogt-Koyanagi-Harada disease in pediatric, adult and elderly: clinical characteristics and visual outcomes.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
2023

TET2-mediated upregulation of 5-hydroxymethylcytosine in LRRC39 promoter promotes Th1 response in association with downregulated Treg response in Vogt-Koyanagi-Harada disease.

Clinical immunology (Orlando, Fla.)
2023

Clinical and multimodal imaging characteristics of eyes with Vogt-Koyanagi-Harada disease: An Egyptian experience.

Oman journal of ophthalmology
2023

Do not discount the diagnosis of VKH based on race: self-reported race and ethnicity of patients with Vogt-Koyanagi-Harada disease in a predominantly white population.

Journal of ophthalmic inflammation and infection
2023

Retinal Pigment Epithelial Characteristics in Acute and Resolved Vogt-Koyanagi-Harada Disease.

Journal of clinical medicine
2023

Vogt-Koyanagi-Harada syndrome in the setting of COVID-19 infection.

Clinical case reports
2023

Checkpoint Inhibitor-Associated Vogt-Koyanagi-Harada Disease Presenting 3 Months Following Discontinuation of Nivolumab.

Ophthalmic surgery, lasers &amp; imaging retina
2023

Incidence and pre/post-treatment risk factors of glaucoma in Vogt-Koyanagi-Harada disease.

International ophthalmology
2023

Sympathetic ophthalmia in an 85-year-old female and a 90-year-old male after a non-complicated cataract surgery: a case report.

The Journal of international medical research
2023

Bilateral Serous Detachments with Roth Spots after COVID-19 Vaccination: A Case Report.

Case reports in ophthalmology
2024

Retrolental Bullous Retinal Detachment as the Presenting Feature of Vogt-Koyanagi-Harada Disease in an Elderly Indian Female: Diagnostic and Therapeutic Challenge.

Ocular immunology and inflammation
2024

The Role of Widefield Optical Coherence Tomography Angiography in the Diagnosis and Management of Acute Vogt-Koyanagi-Harada Disease.

Ocular immunology and inflammation
Ver todos os 881 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Doença de Vogt-Koyanagi-Harada.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Doença de Vogt-Koyanagi-Harada

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Evaluation of Melanin Changes in Acute Vogt-Koyanagi-Harada Disease Using Polarization-Sensitive Optical Coherence Tomography.
    Investigative ophthalmology &amp; visual science· 2026· PMID 41533903mais citado
  2. Natural experiment on neuroinflammatory disease incidence and infection links pre- and post-COVID-19.
    Brain : a journal of neurology· 2026· PMID 41359492mais citado
  3. Seasonal Variations of Vogt-Koyanagi-Harada Disease in Japan: A Study on Long-Term Trends and the Influence of Coronavirus Disease 2019 (COVID-19).
    Ophthalmology science· 2026· PMID 41049114mais citado
  4. Choroidal Osteoma with Focal Choroidal Excavation Masquerading as Active Vogt-Koyanagi-Harada: A Case Report.
    Case reports in ophthalmology· 2026· PMID 41835311mais citado
  5. Incidence of Cataract Surgery and Postoperative Visual Acuity Outcomes in Patients with Vogt-Koyanagi-Harada Disease.
    Ocular immunology and inflammation· 2026· PMID 41774901mais citado
  6. Vogt-Koyanagi-Harada disease recurrence after laser treatment: A case report.
    J Int Med Res· 2026· PMID 41968085recente
  7. Immune-mediated cochleovestibular dysfunction: clinical spectrum from isolated inner-ear disorders to systemic autoimmune diseases and therapeutic strategies.
    Front Immunol· 2026· PMID 41958680recente
  8. Vogt-Koyanagi-Harada Disease with Oral Manifestations: A Rare Case Report.
    Contemp Clin Dent· 2026· PMID 41953911recente
  9. Novel application for the JAK inhibitor baricitinib in the treatment of Vogt-Koyanagi-Harada disease: a prospective cohort study.
    Front Immunol· 2026· PMID 41924279recente
  10. Ultra-Widefield Indocyanine Green Angiography in Uveitis.
    Ocul Immunol Inflamm· 2026· PMID 41919587recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:3437(Orphanet)
  2. MONDO:0018092(MONDO)
  3. GARD:7862(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Artigo Wikipedia(Wikipedia)
  7. Q1238645(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Doença de Vogt-Koyanagi-Harada
Compêndio · Raras BR

Doença de Vogt-Koyanagi-Harada

ORPHA:3437 · MONDO:0018092
Prevalência
Unknown
Herança
Multigenic/multifactorial
CID-10
H20.8 · Outras iridociclites
CID-11
Ensaios
1 ativos
Medicamentos
2 registrados
Início
All ages
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C0042170
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades